Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  New England Journal of Medicine

• Publication date

  1995-04-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJM199504063321401PMID 7877646
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results.

  1995cited by this paper
• Primary chemotherapy in surgically resectable breast cancer

  1995cited by this paper
• Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer.

  1994cited by this paper
• Effect of systemic adjuvant treatment on first sites of breast cancer relapse.

  1994cited by this paper
• Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma.

  1994cited by this paper
• Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes.

  1991cited by this paper
• Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowe

  1990cited by this paper
• Adjuvant systemic therapy for patients with node‐negative tumors

  1990cited by this paper
• The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group.

  1990cited by this paper
• Salvage treatments in relapsing resectable breast cancer.

  1989cited by this paper
• Survival Analysis

  1981cited by this paper
• Dose-response effect of adjuvant chemotherapy in breast cancer.

  1981cited by this paper
• The CMF program for operable breast cancer with positive axillary nodes: Updated analysis on the disease‐free interval, site of relapse and drug tolerance

  1977cited by this paper
• Combination chemotherapy as an adjuvant treatment in operable breast cancer.

  1976cited by this paper
• 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings.

  1975cited by this paper
• Regression Models and Life-Tables

  1972cited by this paper
• Asymptotically Efficient Rank Invariant Test Procedures

  1972cited by this paper

• Day 8 monocyte and lymphocyte counts as a novel and early predictor for discontinuation in gynecologic cancer patients receiving paclitaxel and carboplatin therapy: a retrospective observational study.

  2026cites this paper
• A randomized clinical trial assessing the efficacy of vitamin B prophylaxis in attenuating paclitaxel-induced neuropathy and the imperative use of gabapentin in diabetic ovarian cancer patients

  2026cites this paper
• Survival outcomes and time toxicity of Sandwich versus Sequential chemoradiation in Stage III endometrial cancer: A real-world study stratified by molecular classification.

  2026cites this paper
• Real-world outcomes of anthracycline and taxane-based perioperative breast cancer therapy using the Japanese electronic medical record database.

  2025cites this paper
• Low relative dose intensity adjuvant chemotherapy in elderly patients with breast cancer: predictors and impact on survival.

  2025cites this paper
• Association of neoadjuvant chemotherapy dose intensity with pathological complete response and event-free survival in HER2-negative early breast cancer.

  2025cites this paper
• Prognostic factors and efficacy of postoperative chemotherapy in patients with gastric cancer with positive peritoneal cytology after gastrectomy

  2025cites this paper
• Oncoral Follow-Up for Outpatients Treated with Oral Anticancer Drugs Assessed by Relative Dose Intensity

  2025cites this paper
• Identifying Leukopenia, Renal Dysfunction and Other Factors Limiting Concomitant Chemoradiotherapy in Locally Advanced Cervical Cancer: A Way to Focus on the Importance of Supportive Care and Potentially Improve Treatment Results?

  2025cites this paper
• Body composition as a predictive factor for chemotherapy-induced peripheral neuropathy and dose-limiting toxicity in patients with endometrial cancer undergoing carboplatin and paclitaxel.

  2025cites this paper
• Implications of cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy on hippocampal-dependent cognition and gut microbiome

  2025cites this paper
• Sex differences in toxicity and outcomes in patients with sarcoma treated in the perioperative setting at a comprehensive cancer center

  2025cites this paper
• Omission of breast surgery in exceptional responders after neoadjuvant chemotherapy—what are future possibilities?—a narrative review

  2025cites this paper
• Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trial.

  2025cites this paper
• Clinical features, procalcitonin concentration, and bacterial infection in febrile hospitalized cancer patients: a descriptive study and association analysis

  2025cites this paper
• Exercise May Improve Completion of Standard and Emerging Cancer Treatments.

  2025cites this paper
• Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial

  2025cites this paper
• Management Based on Pretreatment PSMA PET of Patients with Localized High-Risk Prostate Cancer Part 2: Prediction of Recurrence—A Systematic Review and Meta-Analysis

  2025cites this paper
• The timing of surgery for elderly patients with locally advanced breast cancer

  2025cites this paper
• Improving CDK4/6 inhibitors adherence in breast cancer using the CONnected CUstomized Treatment Platform (CONCURxP) mobile health intervention: Study protocol for ECOG-ACRIN EAQ221CD.

  2025cites this paper
• Exploring optimal administration timing of pegylated recombinant human granulocyte colony-stimulating factor for chemotherapy-induced neutropenia in early breast cancer treated with pharmorubicin and endoxan: a prospective randomized controlled clinical trial

  2024cites this paper
• Codelivery of metformin and methotrexate with optimized chitosan nanoparticles for synergistic triple-negative breast cancer therapy in vivo.

  2024cites this paper
• Progress in breast cancer management.

  2024cites this paper
• Impact of adjuvant trastuzumab therapy and its discontinuation on cardiac function and mortality in patients with early-stage breast cancer: An analysis based on the Japanese Receipt Claim Database

  2024cites this paper
• Harnessing physical activity monitoring and digital biomarkers of frailty from pendant based wearables to predict chemotherapy resilience in veterans with cancer

  2024cites this paper
• Combination Therapy with Korean Medicine and Filgrastim on Neutropenia: A Retrospective Study

  2024cites this paper
• Structural Variance of Doxorubicin and Anthracycline Analogues as Topoisomerase Alpha and Beta (Top2a and Top2b) Inhibitors. Potential Design of Analogue Candidates of Less Side Effects on Cardiomyocytes.

  2024cites this paper
• Cost-effectiveness analysis of granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced febrile neutropenia in patients with breast cancer in Taiwan

  2024cites this paper
• Reduction in chemotherapy relative dose intensity decreases overall survival of neoadjuvant chemoradiotherapy in patients with locally advanced esophageal carcinoma

  2024cites this paper
• Cost of Pegfilgrastim for the Prophylaxis of Chemotherapy-induced Febrile Neutropenia in Patients with Breast Cancer Receiving Perioperative Chemotherapy in Daily Practice in Japan: A Posthoc Analysis in a Single-center Retrospective Study.

  2024cites this paper
• The Efficacy Research of Prophylactic PEG-rhG-CSF in Preventing Neutropenia in Early-Stage Breast Cancer Patients Treated With Docetaxel-Based Chemotherapy: A Retrospective Analysis.

  2024cites this paper
• Factors influencing methotrexate pharmacokinetics highlight the need for individualized dose adjustment: a systematic review

  2023cites this paper
• Adjuvant Chemotherapy in Older Women With Early Breast Cancer.

  2023cites this paper
• Impact of Patient Sex on Adverse Events and Unscheduled Utilization of Medical Services in Cancer Patients Undergoing Adjuvant Chemotherapy: A Multicenter Retrospective Cohort Study

  2023cites this paper
• Treatment Changes in Breast Cancer Management and De-Escalation of Breast Surgery.

  2023cites this paper
• Randomized Trial of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With Breast Cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study

  2023cites this paper
• Review Article: Effect Anticancer Drug of Histological Alteration and Improvement their Effects by Natural Antioxidants

  2023cites this paper
• Clinicopathological Risk Factors of Unfavorable Outcomes in Vietnamese Women with Primary Invasive Breast Cancer: A Retrospective Cohort Study

  2023cites this paper
• In-vitro and in-vivo assessment of pH-responsive core-shell nanocarrier system for sequential delivery of methotrexate and 5-fluorouracil for the treatment of breast cancer.

  2023cites this paper
• Radial arterial waves for chemotherapy- and radiotherapy-related myocardial damage identification in patients with breast cancer

  2023cites this paper
• Detailed Sub-study Analysis of the SECRAB Trial: Quality of Life, Cosmesis and Chemotherapy Dose Intensity

  2023cites this paper
• Neutropénie fébrile aux urgences

  2023cites this paper
• Dose Delays, Dose Reductions, and Relative Total Dose Intensity in Patients With Advanced Cancer Who Exercised During Neoadjuvant Chemotherapy Treatment

  2023cites this paper
• Neutropenia febbrile in Pronto Soccorso

  2023cites this paper
• Delivered relative dose intensity in adolescent and young adult germ cell tumours in England: Assessment of data quality and consistency from clinical trials compared to national cancer registration data

  2023cites this paper
• A modular fuzzy expert system for chemotherapy drug dose scheduling

  2023cites this paper
• Impaired microvascular reactivity in patients treated with 5-fluorouracil chemotherapy regimens: Potential role of endothelial dysfunction

  2023cites this paper
• Optimal use of granulocyte colony-stimulating factor prophylaxis to improve survival in cancer patients receiving treatment

  2023cites this paper
• EFFICACY AND SAFETY OF A DEXAMETHASONE-BASED MOUTHWASH TO PREVENT CHEMOTHERAPY-INDUCED STOMATITIS IN WOMEN WITH BREAST CANCER: A MULTICENTRE, OPEN-LABEL, RANDOMISED PHASE 2 STUDY.

  2023cites this paper
• Oncology Phase I Trial Design and Conduct: Time for a Change MDICT Guidelines 2022.

  2022cites this paper
• Immuno-Protective Effect of Aqueous Extract of Ocimum gratissimum Leaf in Cyclophosphamide-Induced Myelotoxicity in Wistar Rat

  2022cites this paper
• A single-arm feasibility phase II study of EMF (erlotinib + methotrexate + 5-fluorouracil) regimen in platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

  2022cites this paper
• An interactive mobile application versus an educational booklet to promote job retention in women undergoing adjuvant chemotherapy for breast cancer: a randomized controlled trial

  2022cites this paper
• Chemotherapy limiting neutropenia. Is prevention required?

  2022cites this paper
• Clinical Trials That Have Informed the Modern Management of Breast Cancer.

  2022cites this paper
• Gasotransmitters in the tumor microenvironment: Impacts on cancer chemotherapy

  2022cites this paper
• Targeting CAR-Nrf2 improves cyclophosphamide bioactivation while reducing doxorubicin-induced cardiotoxicity in triple-negative breast cancer treatment.

  2022cites this paper
• Frequency of measuring body weight in (sub)populations of patients with cancer treated with chemotherapy

  2022cites this paper
• Association between physical activity and neoadjuvant chemotherapy completion and pathologic complete response in primary breast cancer: the CANTO study

  2022cites this paper
• Treatment guideline concordance, initiation, and abandonment in patients with non-metastatic breast cancer from the African Breast Cancer-Disparities in Outcomes (ABC-DO) cohort in sub-Saharan Africa: a prospective cohort study.

  2022cites this paper
• Chemotherapy-Induced Amenorrhea and Its Prognostic Significance in Premenopausal Women With Breast Cancer: An Updated Meta-Analysis

  2022cites this paper
• Targeting CAR and Nrf2 improves cyclophosphamide bioactivation while reducing doxorubicin-induced cardiotoxicity in triple-negative breast cancer treatment

  2022cites this paper
• KASL clinical practice guidelines for management of chronic hepatitis B

  2022cites this paper
• Notch2 Blockade Mitigates Methotrexate Chemotherapy-Induced Bone Loss and Marrow Adiposity

  2022cites this paper
• Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial

  2022cites this paper
• Graphitic Carbon Nitride Nanoheterostructures as Novel Platforms for the Electrochemical Sensing of the Chemotherapeutic and Immunomodulator Agent MTX

  2022cites this paper
• The Effect Of Neutropenia On The Delivery Of Chemotherapy In Breast Cancer Patients At Korle Bu Teaching Hospital In Accra, Ghana

  2022cites this paper
• Chemotherapy-Induced Toxicities and Their Associations with Clinical and Non-Clinical Factors among Breast Cancer Patients in Vietnam

  2022cites this paper
• Effect of Secondary Prophylactic G-CSF on the Occurrence of Febrile Neutropenia in Breast Cancer

  2022cites this paper
• Comparative Protective Effect between Vitamin-E and Royal Jelly on the Liver Injury of Adult Male Albino Rats Induced by Cisplatin (Histological and Ultrastructural Study)

  2022cites this paper
• Mitigating acute chemotherapy-associated adverse events in patients with cancer

  2022cites this paper
• The survival impact of palliative chemotherapy dose modifications on metastatic colon cancer

  2022cites this paper
• Pre-treatment levels of inflammatory markers and chemotherapy completion rates in patients with early-stage breast cancer

  2022cites this paper
• Impact of granulocyte-colony stimulating factor on docetaxel-induced febrile neutropenia in patients with breast cancer

  2021cites this paper
• DMSO reduces the cytotoxicity of anticancer ruthenium complex KP1019 in yeast

  2021cites this paper
• Breast Cancer Mortality in the Americas and Australasia over the Period 1980–2017 with Predictions for 2025

  2021cites this paper
• THE PROTECTIVE EFFECT OF IRBESARTAN AGAINST BLEOMYCIN-INDUCED MALE RATS REPRODUCTIVE TOXICITY

  2021cites this paper
• Feasibility Study of Nanoparticle Albumin-Bound-Paclitaxel and S-1 Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With Operable Breast Cancer: A Prospective Study.

  2021cites this paper
• Effect of healthy diet and exercise on chemotherapy completion rate in women with breast cancer: The Lifestyle, Exercise and Nutrition Early after Diagnosis (LEANer) study: Study protocol for a randomized clinical trial

  2021cites this paper
• Population pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide metabolite in patients with autoimmune glomerulonephritis.

  2021cites this paper
• Prophylaxis of neutropenia with mecapegfilgrastim in patients with non-myeloid malignancies: a real-world study

  2021cites this paper
• CMAR_A_284638 1517..1527

  2021cites this paper
• Prophylactic administration of recombinant human thrombopoietin attenuates XELOX or SOX regimen-induced thrombocytopaenia

  2021cites this paper
• A Single Arm Prospective Pilot Study Examining the Efficacy and Safety of Bevacizumab Single Maintenance Therapy Following Platinum-Based Chemotherapy in Patients with Advanced or Recurrent Cervical Cancer.

  2021cites this paper
• The influence of intervening on the pharmaceutical consultation targeting outpatients with advanced non-small cell lung cancer receiving erlotinib treatment.

  2021cites this paper
• Metastatic Breast Cancer

  2021cites this paper
• Exercise and health-related fitness predictors of chemotherapy completion in breast cancer patients: pooled analysis of two multicenter trials

  2021cites this paper
• Impact of the Relative Dose Intensity of Neoadjuvant Chemotherapy With Anthracycline Followed by Taxane on the Survival of Patients With Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: The JONIE1 Study

  2021cites this paper
• Caffeic Acid, Quercetin and 5-Fluorocytidine-Functionalized Au-Fe3O4 Nanoheterodimers for X-ray-Triggered Drug Delivery in Breast Tumor Spheroids

  2021cites this paper
• The Efficacy and Toxicity of Neoadjuvant Chemotherapy Regimens of Epirubicin Plus Cyclophosphamide Followed by Docetaxel or Paclitaxel in Female Breast Cancer Patients

  2021cites this paper
• Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Endocrinologia (SIE)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper

  2021cites this paper
• Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer.

  2021cites this paper
• Comparison of Treatment Completion Rate Between Conventional and Dose-dense Doxorubicin and Cyclophosphamide (AC) Followed by a Taxane in Patients With Breast Cancer: A Propensity Score-matched Analysis

  2021cites this paper
• Evaluation of radioiodinated ethopabate as a potential tumor targeting agent.

  2021cites this paper
• Analysis of Secondary Leukemia and Myelodysplastic Syndrome After Chemotherapy for Solid Organ Tumors Using the Food and Drug Administration Adverse Event Reporting System (FAERS).

  2021cites this paper
• Locally Advanced Breast Cancer—A Narrative Review of Management in the Indian Scenario

  2021cites this paper
• A Retrospective Analysis of Metronomic Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) Versus Docetaxel and Cyclophosphamide (TC) as Adjuvant Treatment in Early Stage, Hormone Receptor Positive, HER2 Negative Breast Cancer.

  2021cites this paper
• Prophylaxis and treatment strategies for optimizing chemotherapy relative dose intensity

  2021influential citation
• Finding appropriate signal peptides for secretory production of recombinant glucarpidase: an in silico method.

  2021cites this paper
• Immunocorrective treatment use in the prevention of hematological and infectious complications of chemotherapy in cancer patients

  2021cites this paper